相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
James P. Solomon et al.
MODERN PATHOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Pan-cancer analysis of whole genomes
Peter J. Campbell et al.
NATURE (2020)
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al.
NATURE (2020)
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays
Martina Kirchner et al.
GENES CHROMOSOMES & CANCER (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
New clinical trial designs in the era of precision medicine
Elena Garralda et al.
MOLECULAR ONCOLOGY (2019)
Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies
Kai Zimmer et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Testing algorithm for identification of patients with TRK fusion cancer
Frederique Penault-Llorca et al.
JOURNAL OF CLINICAL PATHOLOGY (2019)
Tumour lineage shapes BRCA-mediated phenotypes
Philip Jonsson et al.
NATURE (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives
Fabiana Crispo et al.
CANCERS (2019)
Identifying patients with NTRK fusion cancer
J. P. Solomon et al.
ANNALS OF ONCOLOGY (2019)
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
Nicola J. Curtin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Should next-generation sequencing tests be performed on all cancer patients?
Andrew J. McKenzie et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
National Cancer Institute Basket/Umbrella Clinical Trials MATCH, LungMAP, and Beyond
Alice P. Chen et al.
CANCER JOURNAL (2019)
Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy
Alanna J. Church et al.
MODERN PATHOLOGY (2018)
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma
Sarah Chiang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
The emerging clinical relevance of genomics in cancer medicine
Michael F. Berger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs
Derrick S. Haslem et al.
Oncotarget (2018)
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
Steven G. DuBois et al.
CANCER (2018)
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Pam K. Mangat et al.
JCO PRECISION ONCOLOGY (2018)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Integration of RNA-Seq data with heterogeneous microarray data for breast cancer profiling
Daniel Castillo et al.
BMC BIOINFORMATICS (2017)
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Jaclyn F. Hechtman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells
Jenni Nikkilae et al.
BRITISH JOURNAL OF CANCER (2017)
Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening
Michael K. Kiessling et al.
BMC GENOMICS (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Current practices and guidelines for clinical next-generation sequencing oncology testing
Samuel P. Strom et al.
Cancer Biology & Medicine (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Complexity of FGFR signalling in metastatic urothelial cancer
Alejo Rodriguez-Vida et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele et al.
CANCER DISCOVERY (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
S. Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Epitope landscape in breast and colorectal cancer
Neil H. Segal et al.
CANCER RESEARCH (2008)
Histopathological identification of colon cancer with microsatellite instability
J Alexander et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
分享论文
